Stockreport

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF Immunome (IMNM) is back in focus after announcing that Phase 3 data for its desmoid tumor drug candidate, varegacestat, will be featured in an oral session at the 2026 [Read more]